Accelerate Diagnostics
3950 S. Country Club Road
Suite 470
Tucson
Arizona
85714
United States
Tel: 520-365-3100
Fax: 520-269-6580
Website: http://acceleratediagnostics.com/
Email: contact@axdx.com
134 articles about Accelerate Diagnostics
-
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
3/28/2024
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
-
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
3/7/2024
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results.
-
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
1/19/2024
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.
-
Accelerate Diagnostics Announces Launch of Proposed Public Offering
1/16/2024
Accelerate Diagnostics, Inc. announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.
-
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
1/8/2024
Accelerate Diagnostics, Inc. announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
-
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
11/27/2023
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification.
-
Accelerate Diagnostics Reports Third Quarter 2023 Results
11/9/2023
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023.
-
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
10/30/2023
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time to review 2023 third quarter results.
-
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
8/10/2023
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.
-
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
7/27/2023
Accelerate Diagnostics, Inc. announced that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time to review 2023 second quarter results.
-
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split
7/10/2023
Accelerate Diagnostics, Inc., a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.
-
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
6/13/2023
Accelerate Diagnostics, Inc., a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement.
-
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
5/11/2023
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.
-
Accelerate Diagnostics scheduled call to review 2023 first quarter results
4/27/2023
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time to review 2023 first quarter results.
-
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
3/29/2023
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.
-
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
3/15/2023
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m. Eastern Time to review 2022 fourth quarter and full year results.
-
Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement
3/15/2023
Accelerate Diagnostics, Inc. a leading provider of innovative rapid diagnostic solutions, announced that Steve Reichling will be stepping down as Chief Financial Officer, effective March 31, 2023.
-
Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors
3/8/2023
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023.
-
Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit
12/19/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit.
-
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results
11/14/2022
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.